FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153293603> ?p ?o ?g. }

• W2153293603 endingPage "2313" @default.
• W2153293603 startingPage "2307" @default.
• W2153293603 abstract "Purpose Aberrant Notch signaling has been implicated in the pathogenesis of many human cancers. MK-0752 is a potent, oral inhibitor of γ-secretase, an enzyme required for Notch pathway activation. Safety, maximum-tolerated dose, pharmacokinetics (PKs), pharmacodynamics, and preliminary antitumor efficacy were assessed in a phase I study of MK-0752. Patients and Methods MK-0752 was administered in three different schedules to patients with advanced solid tumors. Hair follicles were collected at higher dose levels to assess a gene signature of Notch inhibition. Results Of 103 patients who received MK-0752, 21 patients received a continuous once-daily dosing at 450 and 600 mg; 17 were dosed on an intermittent schedule of 3 of 7 days at 450 and 600 mg; and 65 were dosed once per week at 600, 900, 1,200, 1,500, 1,800, 2,400, 3,200, and 4,200 mg. The most common drug-related toxicities were diarrhea, nausea, vomiting, and fatigue. PKs (area under the concentration-time curve and maximum measured plasma concentration) increased in a less than dose proportional manner, with a half-life of approximately 15 hours. Significant inhibition of Notch signaling was observed with the 1,800- to 4,200-mg weekly dose levels, confirming target engagement at those doses. One objective complete response and an additional 10 patients with stable disease longer than 4 months were observed among patients with high-grade gliomas. Conclusion MK-0752 toxicity was schedule dependent. Weekly dosing was generally well tolerated and resulted in strong modulation of a Notch gene signature. Clinical benefit was observed, and rational combination trials are currently ongoing to maximize clinical benefit with this novel agent." @default.
• W2153293603 created "2016-06-24" @default.
• W2153293603 creator A5006549117 @default.
• W2153293603 creator A5008909520 @default.
• W2153293603 creator A5013054218 @default.
• W2153293603 creator A5019002225 @default.
• W2153293603 creator A5021209153 @default.
• W2153293603 creator A5021656597 @default.
• W2153293603 creator A5024827085 @default.
• W2153293603 creator A5027438799 @default.
• W2153293603 creator A5028599837 @default.
• W2153293603 creator A5028617710 @default.
• W2153293603 creator A5031142519 @default.
• W2153293603 creator A5032785430 @default.
• W2153293603 creator A5049054322 @default.
• W2153293603 creator A5056893925 @default.
• W2153293603 creator A5060841115 @default.
• W2153293603 creator A5061867713 @default.
• W2153293603 creator A5063863193 @default.
• W2153293603 creator A5067331026 @default.
• W2153293603 creator A5086480662 @default.
• W2153293603 creator A5090305344 @default.
• W2153293603 date "2012-07-01" @default.
• W2153293603 modified "2023-10-16" @default.
• W2153293603 title "Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors" @default.
• W2153293603 cites W1658920532 @default.
• W2153293603 cites W1862474016 @default.
• W2153293603 cites W1959628099 @default.
• W2153293603 cites W1974083062 @default.
• W2153293603 cites W1981539168 @default.
• W2153293603 cites W1984295575 @default.
• W2153293603 cites W2000589976 @default.
• W2153293603 cites W2024373022 @default.
• W2153293603 cites W2052334769 @default.
• W2153293603 cites W2056768114 @default.
• W2153293603 cites W2073551059 @default.
• W2153293603 cites W2081471404 @default.
• W2153293603 cites W2086914247 @default.
• W2153293603 cites W2103592738 @default.
• W2153293603 cites W2141086589 @default.
• W2153293603 cites W2147373929 @default.
• W2153293603 cites W2150388904 @default.
• W2153293603 cites W2155507705 @default.
• W2153293603 cites W2167719915 @default.
• W2153293603 cites W2245227892 @default.
• W2153293603 doi "https://doi.org/10.1200/jco.2011.39.1540" @default.
• W2153293603 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22547604" @default.
• W2153293603 hasPublicationYear "2012" @default.
• W2153293603 type Work @default.
• W2153293603 sameAs 2153293603 @default.
• W2153293603 citedByCount "264" @default.
• W2153293603 countsByYear W21532936032012 @default.
• W2153293603 countsByYear W21532936032013 @default.
• W2153293603 countsByYear W21532936032014 @default.
• W2153293603 countsByYear W21532936032015 @default.
• W2153293603 countsByYear W21532936032016 @default.
• W2153293603 countsByYear W21532936032017 @default.
• W2153293603 countsByYear W21532936032018 @default.
• W2153293603 countsByYear W21532936032019 @default.
• W2153293603 countsByYear W21532936032020 @default.
• W2153293603 countsByYear W21532936032021 @default.
• W2153293603 countsByYear W21532936032022 @default.
• W2153293603 countsByYear W21532936032023 @default.
• W2153293603 crossrefType "journal-article" @default.
• W2153293603 hasAuthorship W2153293603A5006549117 @default.
• W2153293603 hasAuthorship W2153293603A5008909520 @default.
• W2153293603 hasAuthorship W2153293603A5013054218 @default.
• W2153293603 hasAuthorship W2153293603A5019002225 @default.
• W2153293603 hasAuthorship W2153293603A5021209153 @default.
• W2153293603 hasAuthorship W2153293603A5021656597 @default.
• W2153293603 hasAuthorship W2153293603A5024827085 @default.
• W2153293603 hasAuthorship W2153293603A5027438799 @default.
• W2153293603 hasAuthorship W2153293603A5028599837 @default.
• W2153293603 hasAuthorship W2153293603A5028617710 @default.
• W2153293603 hasAuthorship W2153293603A5031142519 @default.
• W2153293603 hasAuthorship W2153293603A5032785430 @default.
• W2153293603 hasAuthorship W2153293603A5049054322 @default.
• W2153293603 hasAuthorship W2153293603A5056893925 @default.
• W2153293603 hasAuthorship W2153293603A5060841115 @default.
• W2153293603 hasAuthorship W2153293603A5061867713 @default.
• W2153293603 hasAuthorship W2153293603A5063863193 @default.
• W2153293603 hasAuthorship W2153293603A5067331026 @default.
• W2153293603 hasAuthorship W2153293603A5086480662 @default.
• W2153293603 hasAuthorship W2153293603A5090305344 @default.
• W2153293603 hasBestOaLocation W21532936031 @default.
• W2153293603 hasConcept C111113717 @default.
• W2153293603 hasConcept C112705442 @default.
• W2153293603 hasConcept C126322002 @default.
• W2153293603 hasConcept C143998085 @default.
• W2153293603 hasConcept C161879069 @default.
• W2153293603 hasConcept C170493617 @default.
• W2153293603 hasConcept C2777288759 @default.
• W2153293603 hasConcept C2780580376 @default.
• W2153293603 hasConcept C2780852908 @default.
• W2153293603 hasConcept C29730261 @default.
• W2153293603 hasConcept C71924100 @default.
• W2153293603 hasConcept C98274493 @default.
• W2153293603 hasConceptScore W2153293603C111113717 @default.

• next